| Literature DB >> 27579049 |
Jin Tao1, Yan Nie1, Yuanyuan Hou1, Xiaoyao Ma1, Guoyu Ding1, Jie Gao1, Min Jiang1, Gang Bai1.
Abstract
Jie-Geng-Tang (JGT), a classic and famous traditional Chinese medicine (TCM) prescription composed of Platycodon grandiflorum (Jacq.) A. DC. (PG) and Glycyrrhiza uralensis Fisch. (GU), is well known for "clearing heat and relieving toxicity" and its ability to "diffuse the lung and relieve sore throat." However, the mechanism underlying its action remains unclear. In this study, potential anti-inflammatory ingredients were screened and submitted to PharmMapper and the KEGG bioinformatics website to predict the target proteins and related pathways, respectively. Differentially expressed candidate proteins from acute lung injury (ALI) mice treated with JGT were identified by isobaric tags for relative and absolute quantitation (iTRAQ) and LC Triple-TOF. Eleven potential anti-inflammatory ingredients were found, including the derivatives of glycyrrhizic acid, licorice-saponin, liquiritin, and platycodigenin. A total of sixty-seven differentially expressed proteins were confirmed after JGT treatment with four therapeutic functions, including immunoregulation, anti-inflammation, ribosome, and muscle contraction. PG and GU comediate PI3K/Akt signal pathway inhibition of NF-κB, VCAM1, and ICAM1 release which primarily act on PI3K, PDK1, AKT, and GSK3β. GU markedly inhibits the ERK/MAPK signaling pathways and primarily acts on LCK, RAS, and MEK. A network was constructed using bioactive ingredients, targets, and pathways to determine the mechanism underlying JGT treatment of ALI.Entities:
Year: 2016 PMID: 27579049 PMCID: PMC4992511 DOI: 10.1155/2016/7379146
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1UPLC/Q-TOF-MS and dual-bioactivity analysis of the JGT extract. (a) UPLC/UV chromatograms of the JGT extract. (b and c) TIC chromatograms in positive ESI mode and negative ESI mode, respectively. (d) Bioactivity chromatograms obtained via the dual-luciferase reporter assay system for NF-κB inhibition. The peak numbers are consistent with those reported in Table 1.
UPLC-DAD/Q-TOF-MS identification of the bioactive constituents in JGT.
| Peak number |
| Identification | Mode | MS ( | Error/ppm | MS/MS | Monoisotopic mass | Composition | Source |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4.2 | 2-(2-Hydroxyphenyl)-succinic acid | Neg. | 209.0509 | 1.96 | 209 [M − H]−; 165 [M − H − CO2]−; 129 [M − H − CO2 − 2H2O]−; | 210.0528 | C10H10O5 | GU |
|
| |||||||||
| 2 | 7.32 | Liquiritin apioside | Pos. | 551.1744 | −3.63 | 551 [M + H]+; 419 [M + H − api]+; 257 [M + H − api − glc]+ | 550.1686 | C26H30O13 | GU |
| Neg. | 549.1657 | 8.9 | 549 [M − H]−; 417 [M − H − api]−; 255 [M − H − api − glc]− | ||||||
|
| |||||||||
| 3 | 7.57 | Liquiritin | Pos. | 419.1335 | 1.67 | 419 [M + H]+; 257 [M + H − glc]+ | 418.1264 | C21H22O9 | GU |
| Neg. | 417.1212 | 6.23 | 417 [M − H]−; 255 [M − H − glc]− | ||||||
|
| |||||||||
| 4 | 8.36 | Platycogenic acid A | Neg. | 533.314 | 4.69 | 533 [M − H]− | 534.3193 | C30H46O8 | PG |
|
| |||||||||
| 5 | 8.97 | Polygalacic acid | Pos. | 505.3437 | 8.72 | 505 [M + H] | 504.3451 | C30H48O6 | PG |
|
| |||||||||
| 6 | 11.55 | Licorice-saponin J2 | Pos. | 825.427 | 0.24 | 825 [M + H]+; 649 [M + H − glu]+; 455 [M + H − glu − Glu]+ | 824.4194 | C42H64O16 | GU |
| Neg. | 823.418 | 7.77 | 823 [M − H]−; 351 [2 × C6H8O6 − H]−; 191 [C6H8O6 − H]− | ||||||
|
| |||||||||
| 6′ | 11.95 | Platycodin D | Pos. | 1225.5932 | − 6.64 | 1225 [M + H]+ | 1224.5775 | C57H92O28 | PG |
| Neg. | 1223.5737 | 3.27 | 1223 [M − H]−; 681 [M − C21H34O16]− | ||||||
|
| |||||||||
| 7 | 13.27 | 22- | Pos. | 881.4104 | − 7.6 | 881 [M + H]+; 705 [M + H − glu]+; 511 [M + H − glu − Glu]+ | 880.4092 | C44H64O18 | GU |
| Neg. | 879.4095 | 9.10 | 879 [M − H]−; 351 [2 × C6H8O6 − H]− | ||||||
|
| |||||||||
| 8 | 14.64 | Licorice-saponin G2 | Pos. | 839.4102 | 4.41 | 839 [M + H]+; 663 [M + H − glu]+; 469 [M + H − glu − Glu]+ | 838.3987 | C42H62O17 | GU |
| Neg. | 837.3927 | 2.15 | 837 [M − H]−; 819 [M − H − H2O]−; 351 [2 × C6H8O6 − H]− | ||||||
|
| |||||||||
| 9 | 15.07 | 22- | Neg. | 863.4142 | 2.43 | 863 [M − H]−; 351 [2 × C6H8O6 − H]− | 864.4144 | C44H64O17 | GU |
|
| |||||||||
| 10 | 15.55 | Glycyrrhizic acid | Pos. | 823.4043 | − 8.86 | 823 [M + H]+; 647 [M + H − glu]+; 453 [M + H − glu − Glu]+ | 822.4038 | C42H62O16 | GU |
| Neg. | 821.3983 | 2.8 | 821 [M − H]−; 351 [2 × C6H8O6 − H]− | ||||||
glc: glucose-H2O; Glu: glucuronide; glu: glucuronide-H2O; api: apiose-H2O.
Figure 2Chemical structures of the bioactive compounds in JGT.
Figure 3Effects of JGT prophylactic administration on acute lung inflammation induced by LPS. (a) HE staining of lung cross sections. The pictures were taken by light microscopy and partially enlarged with 10x magnification. The pathological classification of lung injury shown by the inflammatory infiltration was expressed as the alveolar density (b) and the average gray values of the images (c). Effects of JGT on (d) TNF-α and (e) IL-8 production in the BALF. Values are presented as the mean ± SEM. ### p < 0.001 versus Con group; p < 0.05, p < 0.01, and p < 0.001 versus Mod group (n = 6).
Figure 4Proteomics analysis using mouse lung tissues induced by LPS. (a) Heat map of the iTRAQ differentially expressed protein analysis. (b) Protein interaction analysis by the bioinformatics tool String 9.1.
Figure 5The relationship between the bioactive ingredients and predicted targets and pathways through network pharmacology and AutoDock analysis.
Figure 6Network anti-inflammatory mechanism of JGT on LPS-induced ALI.